<DOC>
	<DOCNO>NCT00019188</DOCNO>
	<brief_summary>RATIONALE : Interleukin-12 may kill tumor cell stop blood flow tumor stimulate person 's white blood cell kill tumor cell . PURPOSE : Phase I/II trial study effectiveness interleukin-12 treating patient AIDS -related Kaposi 's sarcoma .</brief_summary>
	<brief_title>Interleukin-12 Treating Patients With AIDS-Related Kaposi 's Sarcoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose interleukin-12 ( IL-12 ) patient AIDS-associated Kaposi 's sarcoma . II . Determine antitumor activity IL-12 patient . III . Determine effect IL-12 angiogenic factor , include basic fibroblast growth factor , vascular endothelial growth factor , interferon-inducible protein 10 patient . IV . Determine immunologic virologic effect IL-12 patient . PROTOCOL OUTLINE : This dose escalation study . Patients receive interleukin-12 ( IL-12 ) subcutaneously twice week ( least 3 day apart ) 6 month . Patients stable good disease continue IL-12 treatment absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos IL-12 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose limit toxicity . Ten additional patient treat MTD . Patients follow 4 week . PROJECTED ACCRUAL : Up 55 patient enter approximately 4.0 year .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Kaposi</mesh_term>
	<mesh_term>AIDS-Related Opportunistic Infections</mesh_term>
	<mesh_term>Interleukin-12</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Histologically prove Kaposi 's sarcoma ( KS ) At least 5 lesion evaluable noninvasive method No acutely life threaten lesion may responsive therapy Actively bleed critically locate lesion may exclude discretion Study Chair Principal Investigator Asymptomatic pulmonary disease require immediate cytotoxic therapy allow HIVassociated disease AntiHIV serum antibody measure ELISA Western blot Stable dose two follow antiretroviral agent require 4 week prior study : Lamivudine Didanosine Zidovudine Saquinavir Stavudine Ritonavir Zalcitabine Indinavir Nonnucleoside reverse transcriptase inhibitor Other protease inhibitor Antiretroviral therapy unchanged study unless medically warrant Patients may switch antiretroviral agent provide continue receive combination 2 agent Prior/Concurrent Therapy Biologic therapy : At least 6 month since prior interleukin12 ( IL12 ) At least 3 week since prior interferon therapy At least 2 week since prior cytokine bone marrow stimulate factor ( except epoetin alfa ) No concurrent cytokine except epoetin alfa filgrastim ( GCSF ) Chemotherapy : At least 3 week since prior chemotherapy ( least 6 week since prior nitrosoureas mitomycin ) At least 6 month since prior suramin Endocrine therapy : Replacement glucocorticoid allow At least 2 month since prior systemic glucocorticoid dose sufficient affect immune response ( e.g. , 20 mg prednisone equivalent 1 week ) Radiotherapy : At least 3 week since prior radiotherapy Surgery : Not specify Other : See Disease Characteristics At least 3 week since prior antiKS therapy At least 3 week since prior local therapy ( e.g. , intralesional injection ) Patient Characteristics Age : 18 Performance status : Karnofsky 70100 % Life expectancy : Greater 3 month Hematopoietic : Absolute neutrophil count least 750/mm3 Platelet count least 75,000/mm3 Hemoglobin least 9.0 g/dL ( transfusion within 1 month prior entry ) Hepatic : Bilirubin great 3.7 mg/dL direct fraction great 0.2 mg/dL indirect fraction great 3.5 mg/dL AST great 2.5 time upper limit normal No history cirrhosis PT/PTT great 120 % control Renal : Creatinine great 1.5 mg/dL Creatinine clearance least 60 mL/min Other : No hypersensitivity IL12 compound crossreact IL12 No clinically significant autoimmune disease ( e.g. , systemic lupus erythematosus ) rheumatologic disease No active , gross gastrointestinal bleeding uncontrolled peptic ulcer disease No inflammatory bowel disease No severe life threaten infection bacterial , viral , fungal , protozoal , parasitic pathogen within 2 week entry No fever 39 degree Celsius high within 10 day prior entry unless underlie infection rule No second malignancy within 1 year except : Completely resect basal cell carcinoma Carcinoma situ cervix No generalized debilitation mental incapacitation would preclude informed consent No abnormality would score grade 3 toxicity lymphopenia direct manifestation KS Willing refrain unprotected sexual contact activity could result reinfection HIV Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 2 month study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2004</verification_date>
	<keyword>AIDS-related malignancy</keyword>
	<keyword>Kaposi 's sarcoma</keyword>
	<keyword>adult solid tumor</keyword>
	<keyword>body system/site cancer</keyword>
	<keyword>cancer</keyword>
	<keyword>epidemic Kaposi 's sarcoma</keyword>
	<keyword>recurrent Kaposi 's sarcoma</keyword>
	<keyword>skin tumor</keyword>
	<keyword>solid tumor</keyword>
	<keyword>stage , Kaposi 's sarcoma</keyword>
</DOC>